Medpace Investors, LLC

About Medpace Investors, LLC

August J. Troendle, M.D. is the executive most closely associated with Medpace Investors, LLC through his leadership of Medpace Holdings, Inc. He serves as Chief Executive Officer and Chairman of the Board of Directors of Medpace and founded the company in July 1992. Corporate filings also identify him as the sole manager and majority unit holder of Medpace Investors, LLC, which holds a controlling interest in Medpace Holdings. He served as President of Medpace until July 31, 2021. Prior to founding Medpace, Dr. Troendle worked at Sandoz (now Novartis) from 1987 to 1992, where he managed clinical development work focused on lipid-altering agents. Earlier, from 1986 to 1987, he served as a Medical Review Officer in the FDA’s Division of Metabolic and Endocrine Drug Products. His educational background includes a medical degree from the University of Maryland School of Medicine and an MBA from Boston University. This combination of clinical, regulatory, and business training has shaped his long-standing role in clinical research organization leadership. Under his direction, Medpace has grown into a publicly listed global clinical development services company serving pharmaceutical and biotech clients across major therapeutic areas. His leadership is generally associated with disciplined operating execution, a science-driven culture, and long-term strategic continuity. Medpace disclosures also note his broader board experience across public and private companies, including prior service on boards in the biopharmaceutical sector, which underscores his familiarity with governance, capital allocation, and strategic oversight. Overall, his profile reflects a rare blend of medical expertise, regulatory insight, and corporate leadership relevant to the U.S. public markets.